<DOC>
	<DOCNO>NCT00658099</DOCNO>
	<brief_summary>This trial conduct Europe . The aim observational study evaluate change weight type 2 diabetes patient use Levemir® Insulatard® normal clinical practice condition .</brief_summary>
	<brief_title>Observational Study Type 2 Diabetes Patients Failing Oral Anti-diabetic Agents Initiated Levemir® Insulatard®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetes HbA1c great 7.0 % and/or hypoglycaemia variable FBG and/or weight increase selection subject discretion participate physician nontype 2 diabetes current treatment Levemir® Insulatard® hypersensitivity Levemir® Insulatard® excipients woman pregnant , breast feeding intention become pregnant within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>